Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial

Study answer

What this study found

Resveratrol improved follicular oxidative balance and mitochondrial biogenesis and was associated with better oocyte maturity and high-quality embryo outcomes, but it did not significantly improve retrieval, fertilization, total embryo, or pregnancy outcomes. In follicular fluid, TAC was 1.487 ± 0.3257, TOS was 1.885 (0.2490-2.422), and OSI was 1.074 ± 0.9181, with significant improvements versus placebo (TAC P = 0.0009, TOS P = 0.0142, OSI P = 0.0039). Mitochondrial-related markers also improved, including PGC-1α mRNA (P = 0.0032), TFAM mRNA (P = 0.0003), SIRT1 protein (P < 0.0001), PGC-1α…

Study & population

Randomized, triple-blind, placebo-controlled clinical trial in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection at Omid Fertility Clinic in Tehran, Iran (enrollment February 2023 to December 2023).

Intervention

Resveratrol was given orally as 800 mg/day of trans-resveratrol (99% purified; two 400 mg capsules daily) for 60 days before oocyte collection, compared with placebo.

Key limitation

The trial was small, single-center, and short in duration, with only 24 completers in the resveratrol arm.

View full study detailsView sourceOpen PDF

Original abstract